Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Proc Natl Acad Sci U S A ; 111(27): 9983-8, 2014 Jul 08.
Article in English | MEDLINE | ID: mdl-24961373

ABSTRACT

Organic cation transporter 1, OCT1 (SLC22A1), is the major hepatic uptake transporter for metformin, the most prescribed antidiabetic drug. However, its endogenous role is poorly understood. Here we show that similar to metformin treatment, loss of Oct1 caused an increase in the ratio of AMP to ATP, activated the energy sensor AMP-activated kinase (AMPK), and substantially reduced triglyceride (TG) levels in livers from healthy and leptin-deficient mice. Conversely, livers of human OCT1 transgenic mice fed high-fat diets were enlarged with high TG levels. Metabolomic and isotopic uptake methods identified thiamine as a principal endogenous substrate of OCT1. Thiamine deficiency enhanced the phosphorylation of AMPK and its downstream target, acetyl-CoA carboxylase. Metformin and the biguanide analog, phenformin, competitively inhibited OCT1-mediated thiamine uptake. Acute administration of metformin to wild-type mice reduced intestinal accumulation of thiamine. These findings suggest that OCT1 plays a role in hepatic steatosis through modulation of energy status. The studies implicate OCT1 as well as metformin in thiamine disposition, suggesting an intriguing and parallel mechanism for metformin and its major hepatic transporter in metabolic function.


Subject(s)
Fatty Liver/physiopathology , Hypoglycemic Agents/pharmacology , Metformin/pharmacology , Octamer Transcription Factor-1/physiology , Thiamine/metabolism , AMP-Activated Protein Kinases/metabolism , Animals , Carrier Proteins/drug effects , Carrier Proteins/metabolism , Carrier Proteins/physiology , Mice , Mice, Knockout , Octamer Transcription Factor-1/drug effects , Octamer Transcription Factor-1/genetics , Octamer Transcription Factor-1/metabolism , Oxidation-Reduction
2.
Clin Pharmacol Ther ; 89(3): 416-21, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21270793

ABSTRACT

We evaluated the effect of the pregnane X receptor (PXR) agonist rifampin on metformin pharmacokinetics, organic cation transporter 1 (OCT1) and OCT2 mRNA levels, and glucose levels, using the oral glucose tolerance test (OGTT) in 16 healthy subjects. The glucose-lowering effects of metformin were evaluated by OGTT before and after metformin treatment on days 1 and 2 and again on days 13 and 14 after a 10-day course of rifampin. Rifampin increased the difference in maximum glucose levels (ΔG(max)) by 41.9% (P = 0.024) and the area under the concentration-time curve (AUC) during the first 60 min after glucose ingestion (ΔAUC(gluc60)) by 54.5% (P = 0.020). Renal clearance (CL(R)) of metformin was increased by 16% (P = 0.008), but the systemic exposure was only slightly increased (13%, P = 0.049), possibly because of increased absorption. Rifampin increased OCT1 mRNA levels 4.1-fold in peripheral blood cells (P = 0.001); however, OCT2 mRNA was not detected. Our results suggest that rifampin increases OCT1 expression and hepatic uptake of metformin, leading to enhanced glucose-lowering action.


Subject(s)
Hypoglycemic Agents/pharmacokinetics , Metformin/pharmacokinetics , Octamer Transcription Factor-1/genetics , Organic Cation Transport Proteins/genetics , Rifampin/pharmacology , Adult , Antibiotics, Antitubercular/pharmacology , Area Under Curve , Blood Glucose/drug effects , Drug Interactions , Female , Glucose Tolerance Test , Humans , Hypoglycemic Agents/pharmacology , Liver/metabolism , Male , Metformin/pharmacology , Octamer Transcription Factor-1/drug effects , Organic Cation Transport Proteins/drug effects , Organic Cation Transporter 2 , Pregnane X Receptor , Prospective Studies , RNA, Messenger/drug effects , RNA, Messenger/metabolism , Receptors, Steroid/agonists , Time Factors , Young Adult
3.
Am J Pathol ; 167(6): 1477-84, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16314463

ABSTRACT

Cis-platin is an effective anti-neoplastic agent, but it is also highly nephrotoxic. Here, we clearly identify the human organic cation transporter 2 (hOCT2) as the critical transporter for cis-platin nephrotoxicity in isolated human proximal tubules and offer a potential mechanism for reducing nephrotoxicity in clinical practice. Interaction of cis-platin with hOCT2 in kidney or hOCT1 in liver was investigated with the fluorescent cation 4-[4-(dimethyl-amino)styril]-methylpyridinium in stably transfected HEK293 cells and for the first time in tissues physiologically expressing these transporters, human proximal tubules, and human hepatocyte couplets. Cis-platin (100 micromol/L) inhibited transport via hOCT2-HEK293 but not hOCT1-HEK293. In human proximal tubules cis-platin competed with basolateral organic cation transport, whereas it had no effect in tubules from a diabetic kidney or in hepatocytes. In hOCT2-HEK293 cells treated for 15 hours, incubation with cis-platin induced apoptosis, which was completely suppressed by contemporaneous incubation with the hOCT2 substrate cimetidine (100 micromol/L). These findings demonstrate that uptake of cis-platin is mediated by hOCT2 in renal proximal tubules, explaining its organ-specific toxicity. A combination of cis-platin with other substrates that compete for hOCT2 offers an effective option to decrease nephrotoxicity in the clinical setting.


Subject(s)
Cisplatin/toxicity , Kidney/pathology , Octamer Transcription Factor-1/metabolism , Octamer Transcription Factor-2/metabolism , Annexin A5/metabolism , Apoptosis , Cell Line , Humans , Kidney/drug effects , Kinetics , Octamer Transcription Factor-1/drug effects , Octamer Transcription Factor-2/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...